Empiric Antimicrobial Therapy for Polymicrobial Bloodstream Infection
For this polymicrobial bloodstream infection with ESBL-producing E. coli, Bacillus cereus, and Comamonas testosteroni, initiate empiric therapy with a carbapenem (meropenem or imipenem) PLUS vancomycin immediately.
Rationale for Dual Coverage
This recommendation addresses the three distinct pathogens with different resistance profiles and clinical significance:
Coverage for ESBL-Producing E. coli
Carbapenems are the definitive empiric choice for ESBL-producing Enterobacterales bloodstream infections 1, 2. The guidelines consistently recommend carbapenems (imipenem-cilastatin, meropenem, or doripenem) as first-line therapy when ESBL-producing organisms are suspected or confirmed 2.
- Fourth-generation cephalosporins, cefepime, or piperacillin-tazobactam are explicitly listed as alternatives for ESBL producers 1, 2, but carbapenems remain superior for definitive coverage
- Recent evidence shows ESBL-E. coli has high resistance rates to cephalosporins (77-80.6%) and fluoroquinolones (80%), with carbapenems maintaining 87.5% susceptibility 3, 4
- Inappropriate empiric therapy for ESBL bacteremia independently predicts mortality 5, 6
Coverage for Bacillus cereus
Vancomycin is essential for empiric Gram-positive coverage, particularly for Bacillus species. While the guidelines focus primarily on catheter-related infections with staphylococci, vancomycin is recommended for empirical therapy in healthcare settings 7, 1. Bacillus cereus, though rare in bloodstream infections, requires anti-Gram-positive coverage and vancomycin provides this reliably.
- Daptomycin is an alternative if vancomycin MIC >2 μg/mL or nephrotoxicity concerns exist 1
- Linezolid should NOT be used empirically 7, 1
Coverage for Comamonas testosteroni
The carbapenem component adequately covers this rare nosocomial pathogen. C. testosteroni, while uncommon, shows sensitivity to carbapenems (imipenem, meropenem), ceftazidime, and aminoglycosides 8. The carbapenem selected for ESBL coverage simultaneously addresses this organism.
Specific Antibiotic Regimen
Meropenem 1-2g IV every 8 hours (extended infusion over 3 hours preferred) PLUS vancomycin 15-20 mg/kg IV every 8-12 hours (dose-adjusted for renal function, targeting trough 15-20 μg/mL).
Alternative: Imipenem-cilastatin 500mg IV every 6 hours PLUS vancomycin (same dosing).
Critical Management Points
Source Control
- Remove any central venous catheter immediately if present, as polymicrobial bacteremia strongly suggests catheter-related bloodstream infection 7, 9
- The combination of these three organisms (particularly B. cereus and C. testosteroni) is highly suggestive of catheter contamination or catheter-related infection 8
Severity Assessment
- Patients with qSOFA score ≥2 have 9-fold increased 30-day mortality risk regardless of antibiotic appropriateness 10
- Severe sepsis, neutropenia, or immunocompromise mandates aggressive empiric combination therapy 1
Duration Considerations
- Day 1 of therapy = first day of negative blood cultures 7
- Minimum 7-14 days for uncomplicated bacteremia after catheter removal 9
- Extend to 4-6 weeks if persistent bacteremia >72 hours or complications develop 7
Common Pitfalls to Avoid
- Do not use cephalosporins alone for ESBL-E. coli - resistance rates are 77-80% 3, 4
- Do not delay therapy for culture results - inappropriate empiric therapy independently predicts mortality 5, 6
- Do not use piperacillin-tazobactam as monotherapy - while listed as an option for ESBL 2, carbapenems are superior for bloodstream infections
- Do not forget source control - antibiotics alone are insufficient if catheter remains in place 7, 9
De-escalation Strategy
Once susceptibilities return (typically 48-72 hours):
- If ESBL-E. coli is carbapenem-susceptible but also susceptible to piperacillin-tazobactam, consider de-escalation to reduce carbapenem pressure
- Discontinue vancomycin if B. cereus is susceptible to narrower agents
- Adjust based on final susceptibility patterns for all three organisms